Patent · US Active

Engineered anti-IL-23p19 antibodies

US8513389B2 · kind B2 · utility

2Cited by
8References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 22, 2012
Grant dateAug 20, 2013
Priority date—
Expiry dateJun 22, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.